Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Therasse

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
The Lancet. Oncology|May 2, 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trialJohan F Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
The Lancet. Oncology|May 2, 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trialJohan F Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 4